Prostate Cancer Journal Club For Patients
Transdermal estradiol vs traditional ADT – what’s best for you?
Join us for a free Zoom webinar hosted by the Prostate Cancer Journal Club for Patients (PCJCP). We will dive into a groundbreaking study recently published in the New England Journal of Medicine comparing traditional ADT (Lupron, Orgovyx, Firmagon, etc.) with Transdermal Estradiol therapy.
The study found that transdermal estradiol patches applied twice weekly can lower testosterone and fight the cancer as well as traditional ADT, but with a greatly reduced incidence of hot flashes and bone density loss (though it introduces a potential additional side effect).
The webinar is open to anyone interested in learning more about this study, and online attendees will be invited to submit questions for consideration by the moderator.
An abstract is available at https://www.nejm.org/doi/full/10.1056/NEJMoa2511781 and a full text link is also available to those who complete the free NEJM registration.
When: Thursday, August 20, 2026, at 9:00 AM PDT / 12:00 PM EDT
Presented by: Ruth E. Langley, F.R.C.P., Ph.D. and Noel Clarke, Ch.M
Discussant: Dr. Paul Schellhammer
Moderated by: Matthew Cooperberg, MD, MPH (UCSF)
Hosted by: UroToday, The Prostate Cancer Foundation, and UCSF Patient Advocates
About the Prostate Cancer Journal Club for Patients:
The PCJCP bridges the gap between complex medical research and patient care. We break down the latest "game-changing" clinical papers into clear, jargon-free insights, focusing specifically on how new findings directly impact your treatment options.
Our Mission: To empower patients with the knowledge needed to make informed decisions and engage in more effective, collaborative conversations with their medical teams.
Watch past PCJCP sessions